Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 8/20 | 0.47 |
| ▸ | MMP2 | P08253 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488403 | 0.91 | KDM4E (0.61) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL20611920 | 0.86 | XDH (0.41) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL20611918 | 0.82 | EIF4A3 (0.50) | ALOX15KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL24944316 | 0.80 | ALOX15 (0.60) | ALOX15KDM4EALDH1A1RAB9ANPC1 | |
| SCHEMBL21983562 | 0.79 | ALOX15 (0.38) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL2735974 | 0.77 | XDH (0.50) | KDM4EALDH1A1HPGDRAB9ALMNA | |
| SCHEMBL5623372 | 0.76 | KDM4E (0.78) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4166682 | 0.75 | CDK1 (0.49) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL71101 | 0.75 | ALOX15 (0.72) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL17368519 | 0.75 | ALOX15 (0.72) | ALOX15KDM4EALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024029583-A1 | NOVEL PYRAZOLE DERIVATIVE AND USE OF SAME | 国立研究開発法人理化学研究所 | 2024-02-08 | — | — | WO | disclosed |
| US-20230312530-A1 | SALT OF RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, SOLID FORM OF THE SALT, PREPARATION METHOD FOR SAME, AND USES THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312530-A1 | SALT OF RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, SOLID FORM OF THE SALT, PREPARATION METHOD FOR SAME, AND USES THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| WO-2019001572-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | 北京泰德制药股份有限公司 | 2019-01-03 | — | — | WO | disclosed |
| WO-2009007751-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006025979-A9 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1572693-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | ALOX15 1876/4885KDM4E 2711/4885ALDH1A1 1094/4885 |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | MAPKAPK2, MAP3K2, MKNK2 | ALOX15 3087/4885KDM4E 2767/4885ALDH1A1 4638/4885 |
| US-20230312530-A1 | SALT OF RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, SOLID FORM OF THE SALT, PREPARATION METHOD FOR SAME, AND USES THEREOF | ROCK2, ROCK1, ARHGDIB | ALOX15 4477/4885KDM4E 905/4885ALDH1A1 4195/4885 |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | ALOX15 2102/4885KDM4E 2224/4885ALDH1A1 4501/4885 |
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | ALOX15 1526/4885KDM4E 3164/4885ALDH1A1 4171/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | ALOX15 2102/4885KDM4E 2224/4885ALDH1A1 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.